Beta Drugs reduces long-term borrowings by Rs 105.50 crore

Beta Drugs Limited reported Rs 105.50 crore of long-term borrowing repayment for the period ended 30 September 2026, as non-current borrowings fell to Rs 27.83 crore from Rs 133.32 crore at 31 March 2026. The unaudited consolidated cash-flow statement also recorded a Rs 109.30 crore increase in share premium.

How much did Beta Drugs reduce long-term debt?

Beta Drugs reduced long-term borrowings by Rs 105.50 crore in the consolidated cash-flow statement for the period ended 30 September 2026. Its balance-sheet non-current borrowings declined by Rs 105.49 crore to Rs 27.83 crore at 30 September 2026, from Rs 133.32 crore at 31 March 2026.

The funding mix also included higher current borrowings. Current borrowings rose to Rs 20.86 crore at 30 September 2026 from Rs 14.48 crore at 31 March 2026, an increase of Rs 6.38 crore, while total non-current liabilities fell to Rs 37.20 crore from Rs 142.89 crore.

The Rs 105.50 crore long-term borrowing repayment was the largest financing cash-flow item in the September 2026 period. It exceeded the Rs 20.60 crore reported as cash used for non-current investments or acquisition of subsidiary Nivian, while the filing separately recorded a Rs 109.30 crore increase in share premium.

What funded Beta Drugs' financing movements?

Beta Drugs reported a Rs 109.30 crore increase in share premium and a Rs 70.07 lakh increase in share capital, excluding non-cash shares issued to Nivian shareholders. The filing reports these financing movements alongside the Rs 105.50 crore repayment of long-term borrowings, but does not assign share-premium proceeds to a specific repayment or investment.

Net cash from financing activities was Rs 2.50 crore for the period ended 30 September 2026, compared with net cash used in financing activities of Rs 8.07 crore for the year ended 31 March 2026. The two reported periods differ in length, while short-term borrowing cash flow changed to an inflow of Rs 2.64 crore from a Rs 6.01 crore repayment in the prior full year.

Equity share capital stood at Rs 11.12 crore at 30 September 2026, compared with Rs 10.14 crore at 31 March 2026. Other equity increased to Rs 426.58 crore from Rs 234.63 crore, and the balance sheet showed non-controlling interest of Rs 37.02 crore, taking total equity to Rs 474.72 crore from Rs 244.77 crore.

Why did Beta Drugs' cash balance fall despite financing inflows?

Beta Drugs' cash and cash equivalents declined by Rs 21.04 crore to Rs 103.80 crore at 30 September 2026 from Rs 124.85 crore at 31 March 2026. The group generated Rs 28.00 crore from operating activities and Rs 2.50 crore from financing activities, but used Rs 51.54 crore in investing activities.

Working capital used Rs 21.90 crore of cash in the September 2026 period. Trade receivables absorbed Rs 31.49 crore and short-term loans and advances used Rs 7.21 crore, partly offset by a Rs 17.65 crore increase in trade payables; balance-sheet receivables rose to Rs 167.43 crore from Rs 119.13 crore.

Investing cash flows included Rs 22.63 crore spent on tangible and intangible assets, Rs 20.60 crore used for non-current investments or acquisition of subsidiary Nivian, and Rs 11.24 crore used for long-term loans and advances. Interest received of Rs 2.92 crore partly offset these items, leaving net investing cash use at Rs 51.54 crore.

What does the Nivian transaction add to Beta Drugs' balance sheet?

Beta Drugs reported Rs 20.60 crore of cash used for non-current investments or acquisition of subsidiary Nivian during the period ended 30 September 2026. Nivian Lifesciences Private Limited was included in the consolidated results as a 66.09%-owned subsidiary, while the 30 September balance sheet reported Rs 37.02 crore of non-controlling interest.

Intangible assets increased to Rs 101.11 crore at 30 September 2026 from Rs 9.90 crore at 31 March 2026. Total non-current assets rose to Rs 276.69 crore from Rs 160.64 crore, while property, plant and equipment increased to Rs 119.40 crore from Rs 115.37 crore; the filing does not provide a purchase-price allocation for Nivian.

Management identified supply-chain investments to improve Nivian's operating margins as a capital-allocation priority. Its other disclosed priorities include product registrations in key export markets, research and development for new products and novel formulations, and opportunistic oncology investments including biosimilars.

Conclusion

Beta Drugs' September 2026 consolidated statements show debt repayment, equity-related financing and investment occurring in the same reporting period. The group reported Rs 105.50 crore of long-term borrowing repayment, a Rs 109.30 crore increase in share premium, Rs 20.60 crore of Nivian-related investment or acquisition cash use, and a Rs 21.04 crore fall in cash and cash equivalents.

The next disclosures will show progress on management's stated plan to improve Nivian's operating margins through supply-chain efficiencies, alongside product registrations and research and development spending. Movements in trade receivables, which were Rs 167.43 crore at 30 September 2026, will also remain relevant to operating cash generation.